Biological and JAK inhibitor therapy outcomes for severe psoriasis in trisomy 21.
Psoriasis
arthritis
immunology
obesity
trisomy 21
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
08
05
2023
received:
17
01
2023
accepted:
17
05
2023
medline:
5
10
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Little is known about biological outcomes for severe psoriasis in trisomy 21 (T21). Our aim was to review outcomes of patients with T21 and severe psoriasis treated with biologic or Janus kinase inhibitors (JAKi). Information on demographics, co-morbidities, and therapeutic responses was retrospectively collated. Twenty-one patients were identified (mean age 24.7 years). Ninety percent (18/20) of TNFα inhibitor trials failed. Almost two-thirds (7/11) of patients achieved an adequate response with ustekinumab. All three patients treated with tofacitinib achieved an adequate response following at least three biologic failures. The mean number of biologic/JAKi therapies received was 2.1 with overall survival of 36%. Eighty-one percent (17/21) of patients required conversion from their index biologic treatment due to failure. In patients with T21 and severe psoriasis, failure of TNFα inhibition is common and ustekinumab therapy should be considered as first-line therapy. The role of JAKi is emerging.
Identifiants
pubmed: 37288481
doi: 10.1111/1346-8138.16851
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
Janus Kinase Inhibitors
0
Tumor Necrosis Factor-alpha
0
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1339-1342Informations de copyright
© 2023 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Huggard D, Doherty DG, Molloy EJ. Immune dysregulation in children with down syndrome. Front Pediatr. 2020;8:73. Published 2020 Feb 27.
Lam M, Lu JD, Elhadad L, Sibbald C, Alhusayen R. Common dermatologic disorders in down syndrome: systematic review. JMIR Dermatol. 2022;5:e33391.
Weijerman ME, van Furth AM, van der Mooren MD, van Weissenbruch MM, Rammeloo L, Broers CJM, et al. Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with down syndrome. Eur J Pediatr. 2010;169:1195-9.
Enos CW, Ramos VL, McLean RR, Lin TC, Foster N, Dube B, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona psoriasis registry. J Am Acad Dermatol. 2022;86:68-76.
Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628-37.
Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, et al. Trisomy 21 consistently activates the interferon response. Elife. 2016;5:e16220.
Patterson D. Molecular genetic analysis of down syndrome. Hum Genet. 2009;126:195-214.
Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9:25.
Moran B, Gallagher C, Tobin AM, Fletcher JM. Enrichment of polyfunctional IL-17-producing T cells in paradoxical psoriasis skin lesions. J Invest Dermatol. 2020;140:1094-7.
Pham AT, Rachubinski AL, Enriquez-Estrada B, Worek K, Griffith M, Espinosa JM. JAK inhibition for treatment of psoriatic arthritis in down syndrome. Rheumatology. 2021;60:e309-11.
Sobey CG, Judkins CP, Sundararajan V, Phan TG, Drummond GR, Srikanth VK. Risk of major cardiovascular events in people with down syndrome. PLoS One. 2015;10:e0137093.
Sismour B, DʼAcunto K. Down syndrome, severe psoriasis, and increased risk for cardiovascular events. JAAPA. 2019;32:31-3.
Lai F, Mercaldo N, Wang CM, Hersch GG, Rosas HD. Association between inflammatory conditions and Alzheimer's disease age of onset in down syndrome. J Clin Med. 2021;10:3116.
Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176:890-901.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, et al. Comparative efficacy and relative ranking of biologics and Oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther. 2021;11:885-905.